DKSH Holding has announced the acquisition of Swiss Refarmed Group, strengthening its capabilities in the life sciences. Through the acquisition, DKSH Business Unit Performance Materials, the leading global distributor of innovative pharmaceutical ingredients synthesis and
Tags :Homburger
Ahlström Capital, a finnish family-owned investment company, has announced the merger of Swiss-based company Enics with GPV International, owned by Schouw & Co., to create a European electronics giant. The mergering between the two
Credit Suisse Group has priced the issuance of USD 1.65 bn 9.750 per cent. Perpetual Tier 1 Contingent Write-down Capital Notes. The Notes are «high trigger» regulatory capital instruments that are eligible to fulfill
VectivBio Holding a clinical-stage biopharmaceutical company, has announced a combined gross proceeds from public offering and private sale of USD 50 million. On one side, the company has announced the pricing of a follow-on public offering
Julius Baer Group has placed a perpetual non-cumulative Additional Tier 1 (AT1) securities in a USD 400 million transaction with private banks and institutional investors in Asia and Europe. The transaction will help to optimise Julius Baer
Kering completed the sale of Sowind Group, which owns the Swiss watch manufacturers Girard-Perregaux and Ulysse Nardin, to Sowind’s management. The luxury Group has supported the two Houses in their development, strengthened their positioning
Credit Suisse has successfully completed its issuance of €1 billion aggregate principal amount of 2.125% senior notes due 2024 and €750 million aggregate principal amount of floating rate senior notes due 2024. The bonds were issued under Credit Suisse’s
Pwc has completed the sale of its global mobility services business, Vialto Partners, to Clayton, Dubilier & Rice (CD&R). Vialto Partners had previously operated within the PwC network as the Global Mobility Services
Sonova Holding, providers of hearing aid solutions, has completed the placement of CHF 450 million Bonds governed by Swiss law. Application will be made for the Bonds to be listed on the SIX Swiss Exchange. The
CDR-Life, a Swiss biotechnology company pioneering a new and differentiated class of highly tumor-specific immune-oncology therapeutics, has completed its Series A financing raising USD 76 million. The round was led by Jeito Capital and RA Capital
